Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 25, 2008 Brian Lawler	King Triples Down King Pharmaceuticals makes a risky all-in bet on an unproven market.
The Motley Fool May 15, 2007 Brian Lawler	King Fights for Its Empire King Pharmaceuticals announces another good quarter of financial results. Investors should expect more product acquisitions in the coming years.
The Motley Fool May 28, 2008 Brian Lawler	King Pays a Modest Ransom King Pharmaceuticals, a prolific acquirer of other companies' drugs, announces that it had painlessly staked its claim to yet another.
The Motley Fool March 3, 2009 Robert Steyer	Seeking Gain From Pain King Pharmaceuticals tries to remake itself as a pain therapy company.
The Motley Fool February 28, 2008 Brian Lawler	Alpharma on a Mission Alpharma investors take note, the company will launch its Flector pain patch this year, and has other pain drugs in its pipeline that could also make its future anything but painful.
The Motley Fool February 8, 2008 Brian Lawler	Alpharma Doing Its Best Endo Imitation Alpharma sells one of its active pharmaceutical ingredient unit to help finance other businesses.
The Motley Fool August 14, 2008 Brian Lawler	A Potentially Painless PDUFA Date King Pharmaceuticals and Pain Therapeutics get an appointment with the FDA.
The Motley Fool October 31, 2007 Brian Lawler	Alpharma's Loading Up Animal health division sales may have decreased, but the specialty drug developer is expecting renewed growth in its pharmaceutical division.
The Motley Fool June 11, 2008 Brian Lawler	Pain and King Start the Countdown Who will win the race to get approval of an abuse-deterrent drug, Pain Therapeutics or King Pharmaceuticals?
The Motley Fool December 7, 2007 Brian Lawler	Pain Continues as Planned Pain Therapeutics reports on a successful phase 3 trial for its lead drug Remoxy.
The Motley Fool April 1, 2008 Brian Lawler	A Competitive Stab at King and Pain A new, dark-horse competitor, privately held Purdue Pharma, arrives to fight King Pharma and Pain Therapeutics.
The Motley Fool March 1, 2007 Brian Lawler	King Atop Its Throne After two quarters of middling revenue growth, drugmaker King Pharmaceuticals reported blowout sales and operating cash flow for its fourth quarter.
The Motley Fool October 12, 2010 Travis Hoium	King Pharmaceuticals Shares Popped: What You Need to Know King Pharmaceuticals shares are up nearly 40% today after it was announced the company would be purchased by Pfizer Inc.
The Motley Fool August 22, 2007 Brian Orelli	Pain-Free Extrinsic Growth Alpharma licenses a pain-relieving patch. The launch will cut into its near-term earnings, but should help it in 2009 and beyond. Investors, take note.
The Motley Fool August 14, 2009 Brian Orelli	The Real King of the Drug Pushers King Pharma is first up with a tamper-resistant morphine tablet.
The Motley Fool November 10, 2005 W.D. Crotty	Portfolio Pain Relief Pain Therapeutics announces a significant development deal with King Pharmaceuticals. The company's stock is the largest percentage gainer on the Nasdaq -- up 48.9%.
The Motley Fool November 5, 2007 Brian Lawler	King's Abuse-Resistant Bet King Pharmaceuticals signs a development deal with Acura Pharmaceuticals to produce abuse-resistant painkillers. Investors, take note.
The Motley Fool December 11, 2008 Brian Orelli	A Painful Letter from the FDA The FDA smacked down King Pharmaceuticals and Pain Therapeutics with a complete response letter for their application to market Remoxy, an abuse-resistant controlled-release form of oxycodone.
The Motley Fool February 27, 2004 Zeke Ashton	King Makes a Comeback The love/hate cycle might be ready to shift again for this pharmaceutical. King Pharmaceuticals was once a beloved growth stock. Then it became an unloved drug stock suffering from intensifying competition, a poor acquisition or two, and an ongoing SEC investigation. The stock has started to come back.
The Motley Fool December 13, 2007 Brian Lawler	Alpharma Gives to Get The generics drugmaker forecasts its 2008 financials, with guidance of expenses up and income down.
The Motley Fool April 2, 2007 Brian Lawler	Pain Therapeutics Pares Shares The small drugmaker announces a share buyback.
The Motley Fool April 16, 2008 Brian Lawler	Alpharma's Soothing Guidance Alpharma lowers its financial guidance for 2008. Investors, take note.
The Motley Fool November 13, 2006 Brian Lawler	King Not Loving Its Shareholders King Pharmaceuticals appears to be a company with stagnating operations, trying to grow sales via licensing or acquiring new drugs, with (at best) a shaky handling of its accounting practices. Investors, take note.
The Motley Fool May 5, 2008 Brian Lawler	Good News for Abuse-Resistant Drugs Drug developers working on harder-to-abuse pain remedies, including Pain Therapeutics, King Pharmaceuticals, and Alpharma, got a guarded thumbs-up from the FDA last week.
The Motley Fool February 28, 2007 Brian Lawler	Alpharma's Just All Right Drugmaker Alpharma announces its fourth-quarter financial results and reiterates guidance for 2007.
The Motley Fool January 18, 2008 Brian Orelli	The Battle of the Thrombins ZymoGenetics announces that its recombinant thrombin product, Recothrom, was given a thumbs-up by the FDA.
Pharmaceutical Executive June 1, 2006 Sara Calabro	King Without the Crown While most of pharma tries to convince the world that R&D is the number-one priority, one specialty company, King Pharmaceuticals, boasts that it has no lab.
The Motley Fool July 2, 2008 Brian Lawler	DURECT's Intriguing Little Orphan An exciting pain drug inches onward in development.
The Motley Fool October 29, 2004 Bill Mann	King, Knave, or Village Idiot? Troubled King Pharmaceuticals' latest accounting woes threaten to scuttle its merger with Mylan.
The Motley Fool June 24, 2011 Brian Orelli	Come on, Pfizer, Not Even a Little Hint? Remoxy is rejected, but why?
The Motley Fool August 21, 2009 Brian Orelli	ZymoGenetics Goes in for the Kill ZymoGenetics went on the offensive, asking the Food and Drug Administration to pull competitor King Pharmaceuticals' Thrombin-JMI off the market.
The Motley Fool October 6, 2008 Brian Orelli	Cardinal Atones for Its Sins The drugmaker gets its licenses to distribute controlled substances reinstated.
The Motley Fool May 29, 2007 Brian Lawler	The One Development-Stage Drug Stock to Own Now With such a low level of Remoxy sales baked into its share price, and minimal clinical trial risk, investors who consider Pain Therapeutics around today's share price won't be hurting in the long run, if you assume there will be a viable market for abuse-resistant opioids.
The Motley Fool September 6, 2006 Brian Lawler	Catalyst for ZymoGenetics? Trial results for a drug that controls bleeding include a favorable comparison with a similar product. Investors, take note.
The Motley Fool May 13, 2008 Brian Orelli	Omrix's Wild Ride High-growth stocks like Omrix Pharmaceutical can be hard to value. Not only are growing revenues hard to predict, but expenses can fluctuate wildly as the company grows.
The Motley Fool January 30, 2007 Rick Aristotle Munarriz	The King Gives Investors Bread and Circus If Burger King keeps growing with its franchisees as happy as The King himself, royalties will be even more generous. Investors, take note.
The Motley Fool June 20, 2011 Brian Orelli	Pfizer's Pain-Free FDA Approval. More to Come? Oxecta gains FDA approval. Remoxy is up next.
The Motley Fool July 20, 2006 Stephen D. Simpson	Wyeth Wins Again Another respectable quarter and a decent pipeline make this pharmaceutical stock worth watching.
The Motley Fool October 5, 2007 Brian Lawler	OxyContin in the Crosshairs Again The state of Kentucky sues Purdue Frederick over the monetary burden that abusers of the drug OxyContin place on counties within the state.
PC Magazine September 21, 2004	Age of Empires II: The Age of Kings The king of real-time strategy games has yet to be dethroned.
The Motley Fool July 24, 2007 Brian Lawler	Pain and Alpharma Gain From Purdue's Slip Purdue Frederick Company pays a high price for misleading the public about its pain drug OxyContin; other drugmakers stand to benefit from it.
Fast Company Pavithra Mohan	Activision To Buy Candy Crush Creator For $5.9 Billion Activision Blizzard, the company behind video games like Call of Duty and World of Warcraft, just inked a deal to acquire King Digital Entertainment, the maker of wildly popular mobile game Candy Crush Saga.
The Motley Fool February 2, 2006 Rick Aristotle Munarriz	The King of All IPOs Burger King has a Whopper of an IPO on the grill. Going public may actually help as the fast-food restaurant emerges from the privately held shadows and is held financially accountable against its peers.
The Motley Fool August 15, 2006 Jim Mueller	Sonic Goes Dutch at the Drive-In A modified Dutch tender offer will reduce outstanding shares and increase value to shareholders of the drive-in burger purveyor.
Salon.com February 19, 2002 Richard Blow	The chill is gone The once-great Stephen King has been recycling his plots and characters for 20 years now. It's time he made good on his threats to retire...
The Motley Fool December 1, 2008 Brian Orelli	Johnson & Johnson Firms Things Up The health-care giant acquires breast-implant maker Mentor.
The Motley Fool January 25, 2008 Brian Orelli	Where the Big Margins Are Drug company investors get to enjoy such high gross margins, but there's generally only so much improvement that a company can make when it starts from such a high point. Take a look at some pharma companies that are succeeding to do just that.
BusinessWeek July 22, 2010	Hard Choices: Larry King As Larry King Live nears the end of its run, the king of talk remembers his decision to stick with CNN.
The Motley Fool October 31, 2005 Steven Mallas	Marvel Meets the King Marvel Entertainment and Stephen King hook up for a comic book deal. Marvel shareholders should be excited about this.
Bank Systems & Technology August 16, 2010 Matt Gunn	Customer-Centered Banking is the Future, Author Says Brett King discusses his book Bank 2.0 and the future of banking.